Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection
NCT03158077 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 467
Last updated 2017-05-17
Summary
Retrospective observational study, multicentric with Spanish hospitals, in which a switching or change strategy with RAL and ABC / 3TC guidelines was used, in the48 weeks before the start of the study, in order to determine parameters of Effectiveness and security.
Conditions
- HIV Infections
Sponsors & Collaborators
-
Fundacion SEIMC-GESIDA
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-11-15
- Primary Completion
- 2017-04-20
- Completion
- 2017-04-20
Countries
- Spain
Study Locations
More Related Trials
-
An Observational Retrospective Database Analysis to Evaluate Raltegravir Based-regimens, Including NUC-sparing Regimens, in Aged HIV Patients.(RalAge)
NCT03579485 ·Status: UNKNOWN
-
Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors
NCT01480713 ·Status: COMPLETED ·Phase: PHASE3
-
Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed Product
NCT00773708 ·Status: COMPLETED ·Phase: PHASE4
-
Addition of Raltegravir to Established Antiretroviral Suppressive Therapy
NCT01245101 ·Status: TERMINATED ·Phase: PHASE4
-
Observational, Retrospective, Multicenter Study to Describe the Reasons for the Change of the Regimen of Antiretroviral Therapy in HIV Patients
NCT02039921 ·Status: COMPLETED
-
Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy
NCT00718536 ·Status: COMPLETED ·Phase: PHASE4
-
Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir
NCT01294761 ·Status: COMPLETED ·Phase: NA
-
HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen
NCT02513147 ·Status: COMPLETED ·Phase: PHASE4
-
Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen
NCT02577042 ·Status: COMPLETED ·Phase: PHASE4
-
Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression
NCT00554398 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
NCT01213316 ·Status: COMPLETED
-
Renal Transplantation and Raltegravir in HIV-Infected Patients
NCT01453192 ·Status: COMPLETED ·Phase: PHASE3
-
Integrase Resistance Analysis in HIV Patients Who Interrupted Raltegravir Due to Incomplete Viral Suppression
NCT00787774 ·Status: UNKNOWN ·Phase: NA
-
A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
NCT01231516 ·Status: COMPLETED ·Phase: PHASE3
-
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)
NCT01231555 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy of Raltegravir in a Large Urban HIV Clinical Population in Milan
NCT01467349 ·Status: COMPLETED
-
Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)
NCT03667547 ·Status: COMPLETED ·Phase: PHASE4
-
Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1
NCT00781287 ·Status: TERMINATED ·Phase: PHASE4
-
Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients
NCT02995824 ·Status: COMPLETED
-
Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study
NCT03842488 ·Status: UNKNOWN ·Phase: PHASE4
-
Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery
NCT00562510 ·Status: TERMINATED ·Phase: PHASE3
-
Renal and Bone Outcome After Switching Tenofovir to Different Antiretroviral Strategies
NCT02209740 ·Status: COMPLETED
-
Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria
NCT01044771 ·Status: COMPLETED ·Phase: NA
-
Influence of Atorvastatin on Viral Replication During Antiretroviral Treatment Interruption
NCT00355251 ·Status: TERMINATED ·Phase: PHASE4
-
Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.
NCT01258374 ·Status: COMPLETED